1174546-73-6

Basic information

• Product Name: N-cyclohexyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)acetamide
• Synonyms: N-cyclohexyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)acetamide
• CAS NO: 1174546-73-6
• Molecular Weight: 828.994
• Mol File: 1174546-73-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-cyclohexyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-cyclohexyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)acetamide(1174546-73-6)
• EPA Substance Registry System: N-cyclohexyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)acetamide(1174546-73-6)

Safety Data

• Hazardous Substances Data: 1174546-73-6(Hazardous Substances Data)

Upstream product

• 67-30-1 tetrac 
• 538-75-0 dicyclohexyl-carbodiimide 
• 75-65-0 tert-butyl alcohol 
• 1083039-03-5 triisopropylsilyl 2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)acetate 
• 108-91-8 cyclohexylamine 

Downstream Products

• 1174546-76-9 N-cyclohexyl-2-(4-(3,5-diiodo-4-(oxiran-2-ylmethoxy)phenoxy)-3,5-diiodophenyl)acetamide 
• 1259014-89-5 2-(4-(4-(2-chloroethoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)-N-cyclohexylacetamide 

Relevant articles and documents

Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.

Semisynthesis and pharmacological activities of Tetrac analogs: Angiogenesis modulators

Novel Tetrac analogs were synthesized and then tested. Anti-angiogenesis efficacy was carried out using the Chick Chorioallantoic Membrane (CAM) model and the mouse matrigel model for angiogenesis. Pharmacological activities showed Tetrac can accommodate numerous modifications and maintain anti-angiogenesis activity.